The Oncology Institute, Inc. TOI Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by The Oncology Institute, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about The Oncology Institute, Inc.'s stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is The Oncology Institute, Inc.'s stock issuance proceeds?
- The Oncology Institute, Inc. (TOI) reported stock issuance proceeds of $21K in Q1 2026.
- How has The Oncology Institute, Inc.'s stock issuance proceeds changed year-over-year?
- The Oncology Institute, Inc.'s stock issuance proceeds decreased by 84.7% year-over-year, from $137K to $21K.
- What is the long-term trend for The Oncology Institute, Inc.'s stock issuance proceeds?
- Over 2 years (2023 to 2025), The Oncology Institute, Inc.'s stock issuance proceeds has grown at a 948.1% compound annual growth rate (CAGR), from $126K to $13.84M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.